Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Passage BIO, Inc.PASG · Entity 7829 | Chief Financial Officer | July 28, 2023 | August 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Passage BIO, Inc.
Report date July 28, 2023 · Filed August 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,994 |
Ending reported balance
After 2023-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-28 · Exercise / conversion · Acquired 31,250 · Balance 35,447 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Row 2 · 2023-07-28 · Sale · Disposed 11,453 · Balance 23,994 F2: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-28 · Exercise / conversion · Disposed 31,250 · Balance 0 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3: Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3: Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2023 Filed Aug 1, 2023 16:36 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Units · Derivative | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043998 · doc4.xml · derivative · entry 3 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer. F3 · derivative.expiration_date: Represents accelerated vesting of RSUs previously granted pursuant to the 2020 Equity Incentive Plan pursuant to a separation agreement between the Reporting Person and the Issuer. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 16:36 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 11,453 | $0.88 | $10,078.64 |
DisclosureSEC source: 0001209191-23-043998 · doc4.xml · nonDerivative · entry 2 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,994 F2 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 16:36 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043998 · doc4.xml · nonDerivative · entry 1 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 16:28 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024982 · doc4.xml · derivative · entry 3 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 1/4 of the RSUs vested on April 18, 2023, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 16:28 UTC | Passage BIO, Inc. PASG · Entity 7829 | SaleCommon Stock | 2,053 | $1.05 | $2,155.65 |
DisclosureSEC source: 0001209191-23-024982 · doc4.xml · nonDerivative · entry 2 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,053 F2 · kind: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 16:28 UTC | Passage BIO, Inc. PASG · Entity 7829 | Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-024982 · doc4.xml · nonDerivative · entry 1 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| March 15, 2023 Filed Apr 5, 2023 19:29 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001209191-23-023479 · doc4.xml · derivative · entry 1 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The stock option vests as of 1/48 of the total shares monthly beginning on April 15, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 16:23 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-056614 · doc4.xml · derivative · entry 1 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 100% of the total RSUs will vest on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: 100% of the total RSUs will vest on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 17:25 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (right to buy) · Derivative | 159,000 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001209191-22-037054 · doc4.xml · derivative · entry 1 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,000 Underlying: Common Stock · 159,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on July 13, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 16:23 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024942 · doc4.xml · derivative · entry 1 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 1/4 of the RSUs will vest on April 18, 2023, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 1/4 of the RSUs will vest on April 18, 2023, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 17:05 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantStock Option (right to buy) · Derivative | 159,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001787297-22-000003 · primary_doc.xml · derivative · entry 1 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,000 Underlying: Common Stock · 159,000 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 18:44 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantEmployee Stock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $11.43 | $0.00 |
DisclosureSEC source: 0001209191-21-053365 · doc4.xml · derivative · entry 1 King Simona · CIK 0001879312 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2031-08-22 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on August 23, 2022, then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 23, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.